IL4 and asthma: For instance, minocycline, a potent PARP1 inhibitor, can protect against allergen-induced asthma by the means of controlling the T cell receptor (TCR)-nuclear factor κB (NF-κB)-trans-acting T-cell-specific transcription factor (GATA3)-interleukin-4 (IL-4) axis, without a direct modulation of PARP1 activity (Naura et al., 2013).